PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors
NCT ID: NCT05357196
Last Updated: 2022-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
68 participants
INTERVENTIONAL
2020-04-13
2023-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase II trial period: biliary tract cancer
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
NCT03311789
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
NCT03051373
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
NCT00254904
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
NCT00551122
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT04491942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The phase I dose escalation period will adopt a 3+3 dose escalation design. Three dose groups are designed as follows:
Level 1: 150 mg/m2 PT-112 (Phosplatin's platinum) + 1000 mg/m2 gemcitabine; Level 2: 200 mg/m2 PT-112 + 1000 mg/m2 gemcitabine; Level 3: 250 mg/m2 PT-112 + 1000 mg/m2 gemcitabine. If any DLT(Dose-Limiting Toxicity ) occurs in Level 1 group during dose escalation, the dose will be down titrated to Level-1 150 mg/m2 PT-112 + 800 mg/m2 gemcitabine. After the lowest dose group (Level-1 or Level 1), the dose of gemcitabine will be fixed while the dose of PT-112 will be up titrated.
During the phase I dose escalation period, sufficient data will be obtained to demonstrate that the dose is safe. Investigators and sponsor will discuss and decide the initiation time of the phase II period. In phase II, it is planned to enroll subjects with biliary tract cancer according to Simon's two-stage study design, to assess the safety and anti-tumor efficacy of PT-112 in combination with gemcitabine for treating patients with advanced biliary tract cancer. In the first period, 23 evaluable subjects are intended to be enrolled. If ≤ 12 subjects have disease control (CR(Complete Response) + PR(Partial Response) + SD(Stable Disease)) at the first post-baseline tumor assessment, the study drug will be considered to be ineffective and the trial terminated; if \>12 subjects have disease control (CR + PR + SD), the enrollment for phase II will be initiated. In total, 37 evaluable subjects will be enrolled. The study drug will be considered to be ineffective if a total of ≤23 subjects have disease control (CR + PR + SD).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PT-112 in Combination with Gemcitabine Injection
PT-112 in combination with Gemcitabine injection for the treatment of patients with advanced solid tumors
PT-112
Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.
Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PT-112
Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.
Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For phase I dose escalation period only: patients with locally advanced or metastatic solid tumors (including but not limited to biliary tract cancer, pancreatic cancer, ovarian cancer, etc.) confirmed by histopathology or cytology who have failed to respond to standard regimen or have no standard regimen.
3. ECOG(Eastern Cooperative Oncology Group) performance status score of 0-1.
4. Expected survival time greater than 12 weeks.
5. Subjects must have proper organ function and laboratory test results meet the following standards prior to enrollment:
* Basically normal bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 × 109/ L, platelet ≥ 100 × 109/ L, and hemoglobin ≥ 90 g/ L;
* Basically normal liver function: serum albumin ≥ 3.0 g/dL; bilirubin ≤ 1.5 × ULN(upper limit of normal ), ALT(Alanine aminotransferase) and AST( Aspartate transaminase) ≤ 2.5 × ULN; if the patients suffer from liver metastasis or primary liver cancer, ALT or AST ≤ 5 × ULN;
* Normal renal function: creatinine ≤ 1.5 × ULN or creatinine clearance (CL) ≥ 60 mL/min (according to Cockcroft-Gault formula); .Basically normal coagulation function: INR(international normalized ratio) ≤ 1.5 × ULN, APTT(activated partial thromboplastin time) ≤ 1.5 × ULN.
6. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%.
7. subjects with a history of brain metastases who are diagnosed as stable disease by the investigator and do not require additional steroids or anticonvulsants, with radiotherapy or without treatment.
8. Negative serum β-HCG(human chorionic gonadotropin) test for women of childbearing potential (defined as women aged less than 50 years or over 50 years and amenorrheic for less than 12 months prior to screening).
9. Subjects must give informed consent for the study prior to the test and sign the informed consent form.
10. Patients with histologically or cytologically confirmed unresectable or metastatic biliary tract cancer, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC).
11. Patients who have not received systemic treatment for unresectable or metastatic biliary tract cancer or received only one systemic anti-tumor chemotherapy regimen; patients who have received one adjuvant or neoadjuvant chemotherapy regimen and relapsed more than 6 months after the end of chemotherapy can be enrolled.
Exclusion Criteria
2. Active hepatitis, (hepatitis B: HBsAg positive with abnormal liver function and HBV(hepatitis B virus )-DNA ≥ 1000 IU/ml; hepatitis C: HCV(hepatitis C virus)-RNA positive with abnormal liver function).
3. Treatment with corticosteroids \> 20 mg/ day prednisone or other equivalent hormone (unless used to prevent contrast media reactions during radiological procedures), growth factors (eg, erythropoietin, granulocyte colony-stimulating factor, recombinant human thrombopoietin), blood transfusion.
4. The toxic and side effects caused by the subject's previous treatment not recovered to CTCAE Grade ≤ 1, except for alopecia and other events judged to be tolerable by the investigator.
5. Peripheral neuropathy of any grade within 28 days prior to the initiation of study drug.
6. Patients with known sensitivity or hypersensitivity to platinum drugs and/ or gemcitabine.
7. Having received a major surgery within 28 days prior to the initiation of study drug.
8. Having received chemotherapy, biotherapy, radiotherapy, endocrine therapy and targeted anti-tumor therapy (except for nitrosoureas and mitomycin C) within 28 days prior to the initiation of study drug; received nitrosoureas or mitomycin C within 6 weeks prior to the initiation of study drug; received palliative local radiotherapy within 1 week prior to the initiation of study drug; received Chinese herbal medicine with anti-tumor effect within 1 week before the initiation of the study drug.
9. Patients with uncontrollable hypertension (normal range for diastolic blood pressure 60-90 mmHg and for systolic blood pressure 90-140 mmHg ).
10. Requiring systemic treatment for an acute bacterial, viral, or fungal infection, or having an unexplained fever (body temperature \> 38.5℃) during screening prior to the first dose.
11. Patients with moderate to large amount of body cavity effusion to be disposed of.
12. With a known history of psychiatric disorders or drug abuse that may affect compliance.
13. Presence of any of the following conditions within 6 months prior to signing informed consent: uncontrolled congestive heart failure (New York Heart Association class II-IV), angina pectoris, myocardial infarction, stroke (except for lacunar infarction), coronary/ peripheral artery bypass graft surgery, pulmonary embolism.
14. Arrhythmia unable to be controlled by drugs or sustained QTc(corrected QT interval ) interval prolongation, \> 450 msec in males or \> 470 msec in females.
15. Having participated in other clinical studies within 28 days prior to the first dose of the study drug.
16. Pregnant or lactating women.
17. Women of childbearing potential, men of childbearing potential and their partners who are unable to use effective and adequate dual contraception while receiving the study drug and for 3 months after the end of the study.
18. Patient not suitable for participating in the study for any reason judged by the investigator.
19. Patients with advanced biliary tract cancer previously treated with gemcitabine.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SciClone Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tianshu Liu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZhongNan Hospital Of Wuhan University
Wuhan, Hubei, China
General Hospital Of Eastern Theater Command
Nanjing, Jiangsu, China
Zhongshan Hospital Fudan Universtity
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital ZheJiang University School Of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCI-PT112-ONC-P2-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.